* If you want to update the article please login/register
The Rakai Community Cohort Study will determine the epidemiology of malaria infection in children and adolescents/adults by doing surveillance in nearly 320 households selected from two of the ten clusters. Visits include: structured interview/questionnaire of the primary care giver or legal guardian of the child; clinical and laboratory evaluation of each child aged 6 months to ten years; and the primary care giver; and one random randomly selected adolescent/adult resident of the household. In order to link medical information for study participants, the research team will track usage of health clinic or hospital services within the district. In preparation for future malaria vaccination trials, this research will expand the investigators' understanding of pediatric and adult malaria infections in Rakai's Rakai district.
Source link: https://clinicaltrials.gov/ct2/show/NCT01265407
Inducing antibodies in vaccines that prevent parasite growth in the mosquito interrupting transmission caused transmission's mosquito interrupting malaria. In vitro membrane feeding assays using immune sera and laboratory mosquitoes can determine vaccine effectiveness, but field-testing studies are needed to determine transmission blocking efforts in natura. TBV clinical trials have started in Mali, Africa's largest study on the continent, and we expect to extend TBV studies here in Burkina Faso in the future. At Burkina Faso's Sabou Health district area, month, season, and year, this protocol will use a longitudinal cohort to gather data on blood smear positivities by month, season, and year. The mosquito bite rates in locally caught mosquitoes will be determined longitudinally for variations by season and year. Participants aged 0. 5 to 62 years will be screened and mosquito collected at their household every month.
Source link: https://clinicaltrials.gov/ct2/show/NCT04650815
Inducing antibodies that stop parasite growth in the mosquito interrupting transmission leads to virus transmission. In vitro membrane feeding assays using immune sera and laboratory mosquitoes can estimate the effectiveness of vaccines, but field-tested tests are needed to determine transmission blocking efforts in natura. TBV studies in Mali have started elsewhere on the continent, and we predict to expand TBV research in Guinea in the near future. In at Maferinyah sub-prefecture, Guinea, the Maternity sub-prefecture, Guinea, a longitudinal cohort will collect data on malaria transmission based on blood smear positive individuals by month, season, and year. At monthly visits, in association with mosquito collection in/around village residences, Malaria smears will be obtained at monthly visits. The incidences of parasite infection in locally caught mosquitoes will be monitored longitudinally for changes by season and year.
Source link: https://clinicaltrials.gov/ct2/show/NCT04969913
Malaria and HIV have significant interactions on various fronts. HIV infection, severity, and risk for poor treatment outcomes, including mortality and adverse pregnancy outcomes such as anemia and low birth weight, are among the causes of poor treatment outcomes. Malaria infections promote HIV viral replication. Both malaria and HIV are treated with combination therapy to improve treatment results and minimize the risk of resistance formation, thus raising the possibility of drug-drug interactions when the two diseases are treated concomitantly. When the ACT artefantrine was co-administered with efavirenz-based ART to HIV-malaria co-infected individuals, there was a significant decrease in systemic exposure to Artemether, its metabolic precursor dihydroartemisinin, and the long-serving partner drug lumefantrine. Ineffective malaria treatment outcomes such as prolonged morbidity, anemia, death, and poor birth outcomes for pregnant women, as well as rising economic costs and the risk of drug resistance are all risks. Unfortunately, there are currently limited drug options for both malaria and HIV prevention, especially in sub-Saharan Africa, which has made it impossible to maintain drug safety. Detailed Target: To guide malaria treatment for people co-infected with HIV and malaria, use innovative approaches to overcome drug interactions between artemether-lumefantrine and efavirenz. Comparison of a standard dose of artemether-lumefantrine, a pair of the approved dose for height, and a 5-day course of artemether-lumefantrine for the treatment of uncomplicated malaria in HIV-Malaria co-infected individuals receiving efavirenz-based ART.
Source link: https://clinicaltrials.gov/ct2/show/NCT04708496
The study was conducted in parallel in two separate locations, the health districts of Cobly and Tchaourou, both located in northern Benin. Study location and population The study was carried out in parallel. In northern Benin, this is a case control study that focuses on the follow-up of over 12 months of children aged 6 to 59 months. A smear was measured from each sample and transferred to the Center for Expertise and Enhancing Research in Epidemiology and Public Health at the University of Parakou, where a blood smear was prepared from each sample. The second blood sample was obtained at the start of SMC implimentation, and the third sample was collected on the day of the third dose of SMC, the third, six months after the last dose of SMC. With a desiccant, dried blood spots were air dried and stored individually in small Ziploc bags. Anti-PfEMP1 antibody reaction Plasmodium falciparum-encoded variant surface antigens VSA are expressed on the surface of infected erythrocytes and mediate binding to a variety of endothelial cell receptors. Var gene-encoded P. falciparum erythrocyte membrane protein 1 PfEMP1 family in two exon units is the most characteristic of the best-characterized VSA. VAR2CSA is a non-traditional malaria specialist and 25 HIS-tagged CIDR proteins from the three key groups of PfEMP1, merozoite surface protein 1 MSP1 and apical membrane antigen 1 AMA1.
Source link: https://clinicaltrials.gov/ct2/show/NCT05650502
Malaria-related morbidity and mortality have a significant economic impact in endemic areas and pose a significant health risk to non-immune travelers and people living in endemic areas. This screening procedure is designed to continually assess potential healthy volunteers in order to identify potential healthy volunteers in future and ongoing LMIV malaria vaccine, vaccination, or controlled human malaria infections studies.
Source link: https://clinicaltrials.gov/ct2/show/NCT02639299
Plasmodia are injected by female Anopheles mosquitos into the human host, migrate to the liver to reproduce, and then enter red blood cells, resulting in a complex life cycle. The normal signs of malaria with fever episodes are caused by red blood cell bursting as the parasites migrate to infect new cells. Without causing disease itself, the GA2 parasite will prime the immune system for detection of non-attenuated parasites in the future. Therefore, this research is aimed at investigating the safety and tolerability of the GA2 parasite as well as determining its potential protective effectiveness against controlled human malaria infections. The GA2 parasite's effectiveness will be measured against another genetically attenuated parasite, the GA1, which has been shown to be safe and well tolerated in previous studies, but only has limited protective effectiveness, but no protective effect has been reported.
Source link: https://clinicaltrials.gov/ct2/show/NCT04577066
n = 800 Rabies vaccine x 3, n = 600 Rabies vaccine x 3, n = 800 In each group, the third dose of the same vaccine will be administered 12 months after the third dose. The study population is very young: 5-36 month-old children who live permanently in the study area are eligible. Children under the age of 5 months, living in the study area for the remainder of their life are eligible for this program. The primary study objectives remained unchanged 12 months after completion of the primary course, and the primary study goals were determined: Efficacy: To determine the protective efficacy of R21/Matrix-M against clinical malaria caused by Plasmodium falciparum in 5-36 month old children living in a malaria-endemic zone 12 months after completion of the primary course. In 5-36 month old children living in a malaria-endemic zone, the primary course was completed, to determine the protective efficacy of R21/Matrix-M against clinical malaria caused by Plasmodium falciparum in a malaria-endemic area 12 months after completion of the primary course. Despite vaccination policy effectiveness against asymptomatic P. falciparum infection, secondary aims Efficacy against clinical malaria after a booster vaccination program Efficacy against clinical malaria after the primary series and booster vaccinations. A single-vial formulation of R21/Matrix-M This trial is funded by the Serum Institute of India and tests humoral immunogenicity by anti-CSP antibody concentrations 12 months after completion of the primary series of three vaccinations and 12 months after booster vaccinations.
Source link: https://clinicaltrials.gov/ct2/show/NCT04704830
Both AL and DP have similar medical results against uncomplicated falciparum malaria in areas of drug-resistant parasites. The long-life of the partner drug has contributed to the long-term success of the drug against reinfection in DL, but more research into its relative benefits in high-transmission settings relative to AL is required to inform malaria drug policy. In a high malaria transmission zone in northern Zambia, the investigators are comparing the effectiveness of AL and DP for gametocyte clearance and post-treatment chemoprotection among 6- to 59-month-old children with uncomplicated falciparum malaria. Children with microscopy-confirmed Plasmodium falciparum monoinfection will be admitted to 72 hours of directly observed therapy with either AL or DP, serial sampling for parasite clearance, and multi-dose PK measurements will be accepted for 72 hours.
Source link: https://clinicaltrials.gov/ct2/show/NCT04009343
It was first published in trials, but by 1994, it became the first line therapy for all uncomplicated P. falciparum malaria infections in the non-pregnant population. Carrara et al. reported on in vivo PCR-adjusted cure rates in patients treated with MAS3 between 1995 and 2005, as well as the in vitro parasite susceptibility to MAS3 during the same period, and the change in pfmdr1 copy numbers, which increased sharply from 4. 5% before 2001 to 21. 9% after 2002. The number of infections caused by parasites with an elevated pfmdr1 copy number increased from 30% in 1996 to 53% in 2006. Following either 2 mg/kg of artesunate alone for 7 days or 4 mg/kg of mefloquine at both locations, the median parasite clearance time was 84 hours on the Thai side of the international border with Myanmar was 48 hours compared to 48 hours on the Thai side of the Thai border with Myanmar. A recent review of parasite clearance data collected prospectively in patients with uncomplicated hyperparasitaemic malaria has shown a gradual decrease in parasite clearance rates over the past decade, pointing to a decrease in parasite clearance rates in Western Cambodia but with a time lag of a few years. This therapy is more effective against P. falciparum, according to laboratory findings, because it has higher levels of the Pfmdr1 gene, which causes resistance to mefloquine in laboratory experiments.
Source link: https://clinicaltrials.gov/ct2/show/NCT01640587
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions